About Genocea

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines and to identify T cell response signatures of cancer patients treated with checkpoint blockade therapies to potentially improve clinical practice. Genocea expects GEN-003 to be ready to begin Phase 3 development and to file an Investigational New Drug (IND) application for its neoantigen cancer vaccine candidate GEN-009 by the end of 2017.


Stock Quote

+ 0.02 (+0.38%)




Day High


Day Low

Sep 21, 2017 ET on 4:00 PM Delayed at least 20 minutes.

Stock Chart


Sep 27, 2017 at 10:20 AM ET